Honik Llc, Levin Sedran & Berman Llp $44... - Jul 13

The Story

Honik LLC, Levin Sedran & Berman LLP, and Scott+Scott Attorneys at Law LLP announced a $44 million settlement in the In re Chantix (Varenicline) multidistrict litigation, filed in the Southern District of New York. The settlement covers third-party payors or individuals who paid any amount for retail purchases of Chantix from September 29, 2015 through September 17, 2021, and was disclosed in a July 13, 2026 press release.

Why It Matters For Your Portfolio

• $44 million settlement, a defined cash figure that can be modeled into legal reserve and liability estimates, which may affect companies linked to Chantix exposure.
• Purchase window is September 29, 2015 through September 17, 2021, a fixed class period investors can use to scope potential claim pools and exposure.
• Key figures highlighted for analysis include 3.98%, 2.01%, and 0.07%, data points investors can incorporate into valuation or reserve sensitivity testing when assessing legal risk.
• The case is in the Southern District of New York under MDL No. 22-MD-3050, a procedural detail that may affect timing for claims administration and final approval, and therefore potential cash flow impacts.

The Trade

Legal-risk sensitive investors should monitor defendant disclosures, earnings reports, and any company statements about reserve adjustments; this matters for risk positioning but is not a direct buy or sell signal. Watch for court filings on settlement approval and the claims process as the next catalysts, and consider whether the $44 million figure and the provided percentages change your valuation assumptions. Do you have eligible claims? If so, follow the official claims notice for deadlines and eligibility details.